Glysantis™ is a biomedical company active in preclinical research and development of novel nano-medicines. Through our proprietary NanoDendrix™ platform, Glysantis™ is developing therapies for a wide range of clinical indications.
Monodisperse carbohydrate nano-particles are at the core of our technology. Easily modified they can be designed to be novel active ingredients for targeted drug delivery, imaging or diagnostics. They can improve stability, solubility and bioavailability of existing drugs. Their structure and non-toxicity makes it possible to overcome the biological barriers that limit the effectiveness of many therapies today.
Area of Focus :